Hubei Biocause Heilen Pharmaceutical Co., Ltd.

Hubei Biocause Heilen Pharmaceutical Co., Ltd. engages in the pharmaceutical, chemical, and new energy fuel businesses in China and internationally. It is involved in the research and development, production, and sales of chemical raw materials and preparations; and provision of contract research and development, and production services. The company also provides raw material products, including non-steroidal anti-inflammatory raw materials ibuprofen and dexibuprofen, cardiovascular raw materials torsemide and milrinone, anti-tumor raw materials abiraterone acetate, fludarabine phosphate, and granisetron hydrochloride; and preparation products, such as cardiovascular preparations torsemide tablets and non-steroidal anti-inflammatory preparations ibuprofen granules, and other preparations. In addition, it offers non-anti-inflammatory APIs, cardiovascular, anti-tumor, and anticholinergic APIs and intermediates; antipyretic and analgesic, cardiovascular and anti-infective preparations; and chemicals and formulations. Hubei Biocause Heilen Pharmaceutical Co., Ltd. was founded in 1995 and is based in Jingmen, China.